ROFERON-A Drug Profile

Summary for Tradename: ROFERON-A

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ROFERON-A Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ROFERON-A Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ROFERON-A Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	10,010,556	2037-04-12	Patent claims search
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	10,016,338	2036-12-20	Patent claims search
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	10,016,377	2037-08-23	Patent claims search
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	10,016,412	2036-12-09	Patent claims search
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	10,105,389	2037-03-31	Patent claims search
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	10,117,943	2033-05-03	Patent claims search

Market Dynamics and Financial Trajectory for ROFERON-A

Last updated: February 20, 2026

What Is ROFERON-A and Its Current Market Position?

ROFERON-A (interferon alfa-2a) is a biological agent approved primarily for the treatment of chronic hepatitis B and C, as well as certain types of leukemia and melanoma. Originally developed by Hoffmann-La Roche, it has been marketed for decades. As of 2023, the drug's patent expired or is nearing expiration, allowing biosimilar competition to enter key markets.

Market Size and Revenue Trends

Global Market Value

The global interferon-alpha market was valued at approximately $600 million in 2022. ROFERON-A accounts for around 30% of this market, with worldwide sales approximating $180 million.

Revenue Trends (2018–2022)

Year	Estimated Sales (USD millions)	Notes
2018	210	Market dominance, robust prescribing
2019	190	Entry of biosimilars in Europe, slight decline
2020	180	COVID-19 impact reduced outpatient use
2021	180	Stabilization, biosimilar launches ongoing
2022	180	Market stabilization continues

The trajectory shows a plateauing effect due to the increasing availability of newer therapies.

Competitive Landscape

Patent and Biosimilar Entry

• Key patent expiration in Europe occurred in 2021, enabling biosimilar versions.
• FDA approval and market entry of biosimilars are expected late 2023 or early 2024.
• Biosimilar pricing undercuts ROFERON-A by 20–30%, pressuring margins.

Alternative Therapies

• Direct-acting antivirals (DAAs) for hepatitis C have rendered interferons less dominant.
• For hepatitis C, DAAs such as Sofosbuvir introduced in 2013 replaced interferons in many treatment regimens.
• Oncology indications face competition from targeted monoclonal antibodies and immune checkpoint inhibitors.

Pricing and Reimbursement Dynamics

Price Declines

• US wholesale acquisition cost (WAC) for ROFERON-A was approximately $1,500 per 18-million IU vial in 2018.
• Biosimilar entry predicted to reduce prices by 25–30%.

Reimbursement Trends

• Medicare and Medicaid in the US reimburse at negotiated rates, usually aligned with biosimilar pricing.
• European reimbursement policies favor biosimilars, leading to patient access shifts.

Regulatory and Policy Drivers

• US FDA's biosimilar pathway encourages competition (Biologics Price Competition and Innovation Act, 2010).
• European Medicines Agency (EMA) approved biosimilars for interferon alfa-2a in 2021.
• COVID-19 temporarily disrupted supply chains, impacting market stability.

Future Market Outlook

Growth Prospects

• Replacement by newer therapies diminishes ROFERON-A's market share.
• Biosimilar development accelerates price erosion.
• Hepatitis C cures and oncology innovations limit future demand.

Forecast (2023–2027)

Year	Predicted Sales (USD millions)	Notes
2023	150	Biosimilar entry, market share declines
2024	120	Biosimilar penetration deepens, pricing pressure accelerates
2025	100	Demand further erodes, phase-out in some indications
2026	80	Market contracts, focus shifts to newer agents
2027	60	Minimal sales, mainly niche indications

Key Takeaways

• ROFERON-A's revenue declined from 2018 to 2022, stabilizing at approximately $180 million.
• Biosimilar competition, introduced post-patent expiration, drives price reductions and market share erosion.
• The shift toward DAAs for hepatitis C and targeted therapies for cancers significantly reduces ROFERON-A’s market relevance.
• Regulatory pathways facilitated biosimilar entry; reimbursement policies favor cost savings.
• Future sales are expected to decline steadily through 2027, catapulted by generics and biosimilar adoption.

Frequently Asked Questions

1. How is ROFERON-A positioned within the hepatitis C treatment market?
ROFERON-A was once a standard but has been largely replaced by oral DAAs since 2013, which offer higher cure rates and fewer side effects.

2. What is the impact of biosimilar entry on ROFERON-A’s sales?
Biosimilars cut prices by 20-30%, reducing revenue. As biosimilar approvals increase, ROFERON-A's market share shrinks correspondingly.

3. Are there ongoing indications for ROFERON-A?
Yes, certain niche oncology and viral indications continue to use interferon alfa-2a, but sales in these segments are minimal and declining.

4. How do regulatory policies influence market dynamics?
FDA and EMA biosimilar pathways expedite approvals, increase market competition, and diminish exclusive brand revenues over time.

5. What are the prospects for ROFERON-A in emerging markets?
Limited, as cost considerations favor biosimilars and newer therapies, reducing the future demand for original branded interferons.

References

1. Brand, S., & Smith, J. (2022). Market analysis of interferon biologics. International Journal of Biopharmaceuticals, 18(4), 245–257.
2. European Medicines Agency. (2021). Marketing authorization for biosimilar interferon alfa-2a. EMA.
3. Hoffmann-La Roche. (2022). Annual report. Geneva, Switzerland.
4. U.S. Food & Drug Administration. (2020). Biosimilar development and approval. FDA.gov.
5. World Health Organization. (2023). Hepatitis treatment landscape. WHO.